Intravenous SPION-labeled adipocyte-derived stem cells targeted to the brain by magnetic attraction in a rat stroke model: An ultrastructural insight into cell fate within the brain.

Fecha de publicación: 26/09/2021 Fecha Ahead of Print: 26/09/2021

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

García-Belda P
Prima-García H
Ulloa-Navas MJ
Ten-Esteve A
Salom JB
García-Verdugo JM
Gil-Perotín S

Grupos

Investigacion Biomédica en Imagen (GIBI 2-30)

Investigador Principal

Leonor Cerdá Alberich
Unidad Mixta de Investigación Cerebrovascular

Leader

Juan Bautista Salom Sanvalero

Abstract

Mesenchymal stem cell therapy after stroke is a promising option investigated in animal models and clinical trials. The intravenous route is commonly used in clinical settings guaranteeing an adequate safety profile although low yields of engraftment. In this report, rats subjected to ischemic stroke were injected with adipose-derived stem cells (ADSCs) labeled with superparamagnetic iron oxide nanoparticles (SPIONs) applying an external magnetic field in the skull to retain the cells. Although most published studies demonstrate viability of ADSCs, only a few have used ultrastructural techniques. In our study, the application of a local magnetic force resulted in a tendency for higher yields of SPION-ADSCs targeting the brain. However, grafted cells displayed morphological signs of death, one day after administration, and correlative microscopy showed active microglia and astrocytes associated in the process of scavenging. Thus, we conclude that, although successfully targeted within the brain, SPION-ADSCs viability was rapidly compromised.

Datos de la publicación

ISSN/ISSNe:: 1549-9634, 1549-9642
Tipo:: Article
Páginas:: 102464-102464
DOI:: 10.1016/j.nano.2021.102464
Factor de Impacto:: 1,019 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

García-Belda P:: 1Laboratory of Comparative Neurobiology, Institute Cavanilles, University of Valencia, Valencia, Spain.
Prima-García H:: 2Instituto de Ciencia Molecular (ICMol), Universitat de València, Paterna, Spain.
Aliena-Valero A:: Instituto de Investigación. 3Unidad Mixta de Investigación Cerebrovascular, Instituto de Investigación Sanitaria La Fe-Universidad de Valencia, Valencia, Spain.
Castelló-Ruiz M:: Instituto de Investigación. 4Unidad Mixta de Investigación Cerebrovascular, Instituto de Investigación Sanitaria La Fe-Universidad de Valencia, Valencia, Spain; Departamento de Biología Celular, Biología Funcional y Antropología Física, Universidad de Valencia, Burjassot, Spain.
Ulloa-Navas MJ:: 1Laboratory of Comparative Neurobiology, Institute Cavanilles, University of Valencia, Valencia, Spain.
Ten-Esteve A:: Instituto de Investigación. 5Biomedical Imaging Research Group (GIBI230), La Fe Health Research Institute, Valencia, Spain.
Martí-Bonmatí L:: Instituto de Investigación. 5Biomedical Imaging Research Group (GIBI230), La Fe Health Research Institute, Valencia, Spain.
Salom JB:: Instituto de Investigación. 6Unidad Mixta de Investigación Cerebrovascular, Instituto de Investigación Sanitaria La Fe-Universidad de Valencia, Valencia, Spain; Departamento de Fisiología, Universidad de Valencia, Valencia, Spain.
García-Verdugo JM:: 7Laboratory of Comparative Neurobiology, Institute Cavanilles, University of Valencia, Valencia, Spain.
Gil-Perotín S:: Instituto de Investigación. 8Laboratory of Central Neuroimmunology, IIS Hospital La Fe, Valencia, Spain.